• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Presenting on Emerging Growth Conference 87 Day 2 on October 23; Register to live stream

    10/22/25 7:00:00 AM ET
    $ATCH
    $CIA
    $CLNN
    $CRVO
    Finance: Consumer Services
    Finance
    Life Insurance
    Finance
    Get the next $ATCH alert in real time by email

    MIAMI, Oct. 22, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 87th Emerging Growth Conference on October 22 & 23, 2025.

    The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.

    Register for the Conference here.

    Submit Questions for any of the presenting companies to:

    Questions@EmergingGrowth.com

    For updates, follow us on Twitter

    Day 1 - Today

    October 22, 2025

    9:00

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    9:35

    Introduction

    9:40 – 10:10

    African Discovery Group, Inc. (OTCID: AFDG)

    Keynote speakers: Alan Kessler, Chairman / Director Copper Intelligence, Andrew Groves, Future Chairman Copper Intelligence & Aldo Cesano Director Copper Intelligence.

    10:15 – 10:45

    AtlasClear Holdings, Inc. (NYSE:ATCH)

    Keynote speakers: Craig Ridenhour, President & John Schaible, Chairman and CEO

    10:50 – 11:20

    West Red Lake Gold Mines Ltd. (OTCQB:WRLGF) (TSXV:WRLG)

    Keynote Speaker: Gwen Preston, Vice President, Communications

    11:25 – 11:55

    CervoMed Inc. (NASDAQ:CRVO)

    Keynote speaker: Matt Winton - Chief Commercial and Business Officer

    12:00 – 12:30

    CyberCatch Holdings, Inc. (TSXV:CYBE) (OTCQB:CYBHF)

    Keynote speaker: Sai Huda, CEO

    1:45 – 2:15

    CopAur Minerals, Inc. (OTCQB:COPAF) (TSXV:CPAU)

    Keynote speaker: Andrew Neale - CEO

    2:55 – 3:05

    Citizens, Inc. (NYSE:CIA)

    Keynote speakers: Jon Stenberg, President / CEO, and Jeff Conklin, CFO

    3:25 – 3:35

    Vista Gold Corp. (NYSE:VGZ) (TSX:VGZ)

    Keynote speaker: Frederick Earnest, CEO

    3:40 – 3:50

    Kobo Resources, Inc. (OTCQB:KBRIF) (TSXV:KRI)

    Keynote speakers: Edouard Gosselin, Director, CEO and Corporate Secretary & Paul Sarjeant, Director, President and COO

    3:55 – 4:05

    BluSky AI Inc. (OTCID: BSAI)

    Keynote speaker: Trent D'Ambrosio, Founder, CEO, and Dan Gray, COO

    4:10 – 4:20

    Immuron Limited (NASDAQ:IMRN)

    Keynote speaker: Steve Lydeamore, CEO

    4:25 – 4:35

    C3 Metals Inc. (TSXV:CCCM) (OTCQB:CUAUF)

    Keynote speaker: Daniel A. Symons, President, CEO & Director

    _______________________________________________________________

    Day 2 – Tomorrow

    October 23, 2025

    10:00

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    10:45

    Introduction

    10:50 – 11:20

    Imagion Biosystems Limited. (CXA: IBX) (ASX: IBX)

    Keynote speakers: Robert Romeo Proulx, Executive Chairman & Ward Detwiler, Chief Business Officer

    11:25 – 11:55

    HydroGraph Clean Power Inc. (OTCQB:HGRAF) (CSE:HG)

    Keynote speaker: Kjirstin Breure, President and CEO

    12:00 – 12:30

    Uranium American Resources Inc. (OTCID: UARI)

    Keynote speaker: Willian Hunger, Acting CEO

    12:35 – 1:05

    Walker Lane Resources Ltd. (TSXV:WLR) (OTC:CMCXF) (Frankfurt: 6YL)

    Keynote speaker: Kevin Brewer, CEO, President & Director

    1:10 – 1:40

    Signature Resources Ltd. (TSXV:SGU) (OTCQB:SGGTF) 

    Keynote speaker: Dan Denbow, President, CEO & Director

    1:45 – 2:15

    Nova Minerals Limited (NASDAQ:NVA) (ASX: NVA)

    Keynote speaker: Christopher Gerteisen – CEO & Executive Director

    2:20 – 2:50

    First Phosphate Corp. (CSE:PHOS) (OTCQX:FRSPF) (FSE: KD0)

    Keynote speaker: John Passalacqua, CEO

    3:10 - 3:20

    Clene Inc., (NASDAQ:CLNN)

    Keynote speakers: Rob Etherington, President / CEO

    3:25 – 3:35

    Lahontan Gold Corp. (TSXV:LG) (OTCQB:LGCXF)

    Keynote speaker: Kimberly Ann, President / CEO

    3:40 – 3:50

    Gossamer Bio, Inc. (NASDAQ:GOSS)

    Keynote speaker: Bryan Giraudo, CFO & COO

    4:10 – 4:20

    Regen BioPharma Inc. (OTC:RGBP)

    Keynote speakers: David Koos, President / CEO, & Harry M. Lander, Ph.D. Senior Scientific Consultant



    4:25 – 4:35

    Star Gold Corp. (OTCQB:SRGZ)

    Keynote speaker: Lindsay E. Gorrill, Chairman & CEO

    4:40 – 4:50

    Eloro Resources, Ltd. (OTCQX:ELRRF) (TSX:ELO)

    Keynote speakers: Chris Holden, VP Corporate Development

    Register for the Conference here.

    Submit Questions for any of the presenting companies to:

    Questions@EmergingGrowth.com

    Replays: Subscribe to our YouTube Channel

    About EmergingGrowth.com

    Founded in 2009, Emerging Growth.com quickly became a leader in its space and has developed an extensive history of identifying emerging growth companies that can be overlooked by the investment community.

    About the Emerging Growth Conference

    The Emerging Growth Conference is an effective way for public companies to engage with the investment community regarding their Company, new products, services and other major announcements from anywhere, in an effective and time efficient manner.

    All sessions are conducted through video webcasts. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients. Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future. In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any virtual handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with an offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com.

    If you believe or know of a company that might fit our audience, contact us here.

    Thank you for your interest in our conference, and we look forward to your participation in future conferences.

    Contact:

    Emerging Growth

    Phone: 1-305-330-1985

    Email: Conference@EmergingGrowth.com



    Primary Logo

    Get the next $ATCH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATCH
    $CIA
    $CLNN
    $CRVO

    CompanyDatePrice TargetRatingAnalyst
    Gossamer Bio Inc.
    $GOSS
    3/23/2026Overweight → Neutral
    Cantor Fitzgerald
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$1.00Outperform → Neutral
    Wedbush
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$0.30Overweight → Equal Weight
    Barclays
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$1.00Outperform → Market Perform
    Leerink Partners
    Gossamer Bio Inc.
    $GOSS
    1/28/2026$9.00Overweight
    Barclays
    CervoMed Inc.
    $CRVO
    12/18/2025Overweight
    Cantor Fitzgerald
    Gossamer Bio Inc.
    $GOSS
    9/10/2025$9.00Neutral → Buy
    UBS
    Gossamer Bio Inc.
    $GOSS
    7/14/2025$11.00Sector Outperform
    Scotiabank
    More analyst ratings

    $ATCH
    $CIA
    $CLNN
    $CRVO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immuron CEO, Steven Lydeamore presentation at Kalkine Media Webinar

    MELBOURNE, Australia, July 20, 2026 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Kalkine Media Webinar on Monday, 20th July 2026 (12:30pm Australian Eastern Time). A copy of the presentation slide deck is available on the Company’s website: https://investors.immuron.com.au/announcements/7639968 This release has been authorised by the directors of Immuron Limited. COMPANY CONTACT:Steven LydeamoreChief Executive Officersteve@immuron.com           About ImmuronImmuron Limited ((ASX: IMC, NASDAQ:IMRN), is an Australian biopharmaceutical company focused on developing and commerci

    7/20/26 6:00:00 AM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year

    Sales Highlights (unaudited):Global FY26 sales AUD$7.7 million up 6% on prior comparative period (pcp)2H FY26 sales AUD$3.5 million up 7% on pcp4Q FY26 sales AUD$2.0 million up 2% on pcp Australia FY26 sales AUD$5.8 million up 10% on pcp2H FY26 sales AUD$2.5 million up 6% on pcp4Q FY26 sales AUD$1.6 million up 1% on pcp Canada FY26 sales AUD$0.2 million down 55% on pcp2H FY26 sales AUD$0.1 million up >1000% on pcp4Q FY26 sales up 376% on pcp USA FY26 sales AUD$1.8 million up 7% on pcpFY26 sales USD$1.2 million up 13% on pcp 2H FY26 sales AUD$0.9 million down 1% on pcp2H FY26 sales USD$0.6 million up 9% on pcp

    7/16/26 6:00:00 AM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)

    BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB) New analyses of Phase 2b clinical trial reinforce treatment effect of neflamapimod observed relative to placebo in "pure" DLB and support selection of 50 mg TID for planned Phase 3 study in DLB Neflamapimod produced durable slowing of basal forebrain atrophy and increased basal forebrain connectivity relative to placebo in trial, reinforcing the basal forebrain as a key therapeutic target in DLB New Phase 2 study showed an 80 mg twice-daily dose of neflamapimod met its primary safety, tolerabi

    7/14/26 7:30:00 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATCH
    $CIA
    $CLNN
    $CRVO
    SEC Filings

    View All

    SEC Form 6-K filed by Immuron Limited

    6-K - Immuron Ltd (0001660046) (Filer)

    7/20/26 9:37:41 PM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Immuron Limited

    6-K - Immuron Ltd (0001660046) (Filer)

    7/20/26 8:00:19 AM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Immuron Limited

    6-K - Immuron Ltd (0001660046) (Filer)

    7/15/26 9:28:55 PM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATCH
    $CIA
    $CLNN
    $CRVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Gerteisen Christopher bought $13,848 worth of shares (2,007 units at $6.90), increasing direct ownership by 1% to 143,698 units (SEC Form 4)

    4 - Nova Minerals Corp (0001852551) (Issuer)

    7/17/26 4:54:12 PM ET
    $NVA
    Precious Metals
    Basic Materials

    SEC Form 4 filed by CFO and General Counsel Patel Sandip I

    4 - AtlasClear Holdings, Inc. (0001963088) (Issuer)

    7/16/26 8:21:33 PM ET
    $ATCH
    Finance: Consumer Services
    Finance

    SEC Form 4 filed by Director Carlson Steven J.

    4 - AtlasClear Holdings, Inc. (0001963088) (Issuer)

    7/16/26 8:17:13 PM ET
    $ATCH
    Finance: Consumer Services
    Finance

    $ATCH
    $CIA
    $CLNN
    $CRVO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Gerteisen Christopher bought $13,848 worth of shares (2,007 units at $6.90), increasing direct ownership by 1% to 143,698 units (SEC Form 4)

    4 - Nova Minerals Corp (0001852551) (Issuer)

    7/17/26 4:54:12 PM ET
    $NVA
    Precious Metals
    Basic Materials

    Director Boger Joshua S bought $3,000,000 worth of shares (955,414 units at $3.14) (SEC Form 4)

    4 - CervoMed Inc. (0001053691) (Issuer)

    6/15/26 5:37:36 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Stenberg Jon bought $48,192 worth of Citizens (10,000 units at $4.82), increasing direct ownership by 3% to 327,574 units (SEC Form 4)

    4 - CITIZENS, INC. (0000024090) (Issuer)

    5/26/26 10:28:12 AM ET
    $CIA
    Life Insurance
    Finance

    $ATCH
    $CIA
    $CLNN
    $CRVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Gossamer Bio downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Gossamer Bio from Overweight to Neutral

    3/23/26 8:26:50 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio downgraded by Wedbush with a new price target

    Wedbush downgraded Gossamer Bio from Outperform to Neutral and set a new price target of $1.00

    2/24/26 8:01:18 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio downgraded by Barclays with a new price target

    Barclays downgraded Gossamer Bio from Overweight to Equal Weight and set a new price target of $0.30

    2/24/26 7:42:57 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATCH
    $CIA
    $CLNN
    $CRVO
    Leadership Updates

    Live Leadership Updates

    View All

    Nova Minerals Appoints Former JP Morgan Metals & Mining Professional to Board as Company Advances U.S. Critical Metals Strategy

    Anchorage, Alaska, July 01, 2026 (GLOBE NEWSWIRE) -- Nova Minerals Corp ("Nova Minerals" or the "Company") is pleased to announce the appointment of Mr. Joshua Girnun to the Company’s Board of Directors, effective July 1, 2026. Mr. Girnun brings institutional finance and risk underwriting experience from his background at JP Morgan Chase & Co., where he co-founded a client-facing risk underwriting team covering the metals and mining, energy, renewables, industrials, oil and gas, and agriculture sectors. He pairs his financial background with strong technical training, holding two master’s degrees spanning resource finance and geosciences, in addition to an honours degree and a bachelor’s i

    7/1/26 6:30:00 AM ET
    $NVA
    Precious Metals
    Basic Materials

    Vista Gold Strengthens the Mt Todd Project Execution Team with the Appointment of Julie Jones as General Counsel and Company Secretary and Advances Search for a Managing Director

    Vista Gold Corp. (NYSE American and TSX:VGZ) is pleased to announce the appointment of Julie Jones as General Counsel and Company Secretary of Vista Gold Australia Pty Ltd. Ms. Jones will be based in the Company's Perth office and will play an important role in establishing the Mt Todd gold project as a leading gold producer in Northern Territory, Australia. The appointment reflects Vista's continued focus on strengthening its executive project execution capabilities as the Company advances Mt Todd, one of the largest undeveloped gold projects in Australia. Ms. Jones brings more than 20 years of legal and executive leadership experience across ASX100 companies, global mining operators, an

    5/13/26 5:01:00 PM ET
    $VGZ
    Precious Metals
    Basic Materials

    CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

    SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, announces the appointment of Eric Francois to the Company's Board of Directors. "Eric's decades of financial, transactional and operational experience will make an immediate impact to CERo's board of directors," said Chris Ehrlich, Company Chairman and Chief Executive Officer. "Furthermore, his expertise in capital raising, M&A, and business development will be an impactful addition at this stage of our development." Mr. Francois is an executive with over 25

    2/17/26 8:00:00 AM ET
    $CERO
    $CRVO
    $SCYX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ATCH
    $CIA
    $CLNN
    $CRVO
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Gossamer Bio Inc. on Jun 21

    Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects. Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownershi

    6/21/24 3:17:31 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATCH
    $CIA
    $CLNN
    $CRVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AtlasClear Holdings Inc.

    SC 13D/A - AtlasClear Holdings, Inc. (0001963088) (Subject)

    11/14/24 5:00:29 PM ET
    $ATCH
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SC 13G/A filed by Clene Inc.

    SC 13G/A - Clene Inc. (0001822791) (Subject)

    11/14/24 3:32:55 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Clene Inc.

    SC 13G - Clene Inc. (0001822791) (Subject)

    11/14/24 3:26:45 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATCH
    $CIA
    $CLNN
    $CRVO
    Financials

    Live finance-specific insights

    View All

    Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

    Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the early tender results of its previously announced exchange offer (the "Exchange Offer") to exchange any and all of its 5.00% Convertible Senior Notes due 2027 (the "Existing Convertible Notes") for a pro rata portion of (i) up to $72.0 million in aggregate principal amount of its new 7.50% Convertible Senior Secured First Lien Notes due 2030 (the "New Convertible Notes"), (ii) up to

    6/3/26 8:00:00 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update

    - FDA Confirms In-Person Pre-NDA Type B Meeting in Mid-June - - Positive PROSERA CT FRI Results Demonstrated Multiple Statistically Significant Treatment Effects, Including Novel Signals Correlated with Clinical Outcomes - - Gossamer Announces Commencement of Exchange Offer and Consent Solicitation for Outstanding 5.00% Convertible Senior Notes Due 2027 - - Cash, cash equivalents and marketable securities totaled $99 million as of March 31 - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with in

    5/18/26 7:00:00 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026

    Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it will report its first quarter 2026 financial results on Monday, May 18, 2026. In connection with the earnings release, Gossamer's management team will host a live conference call and webcast at 8:00 a.m. ET on Monday, May 18, 2026, to discuss the Company's financial results and provide a corporate update. Domestic Dial-in Number: 1-800-715-9871 International Dial-in Number: 1-646-307-1963

    5/15/26 7:01:00 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care